MTOR and metabolic dysfunction-associated steatotic liver disease: Empagliflozin could significantly ameliorate liver injury in an animal model of T2DM with NAFLD, through enhancing hepatic macrophage autophagy via the AMP-activated protein kinase/mechanistic target of rapamycin (AMPK/mTOR) signaling pathway and further inhibiting hepatic inflammatory responses [114].